The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center

Ricardo L. Favaretto, Shahrokh F. Shariat, Daher C. Chade, Guilherme Godoy, Ari Adamy, Matthew G. Kaag, Bernard H. Bochner, Jonathan Coleman, Guido Dalbagni

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Background: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. Objective: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. Design, setting, and participants: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. Intervention: All patients were treated with RNU. Measurements: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p = 0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p = 0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p = 0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p = 0.2). On multivariate analysis, pathologic stage (p < 0.0001) and nodal status (p = 0.01) were associated with worse CSS. This study is limited by its retrospective nature. Conclusions: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.

Original languageEnglish (US)
Pages (from-to)574-580
Number of pages7
JournalEuropean Urology
Volume58
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Recurrence
Neoplasms
Survival
Carcinoma
Kidney
Kidney Pelvis
Cystectomy
Survival Analysis
Ureter
Urinary Bladder Neoplasms
Tertiary Care Centers
Survivors
Urinary Bladder
Multivariate Analysis
Survival Rate
Regression Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Favaretto, Ricardo L. ; Shariat, Shahrokh F. ; Chade, Daher C. ; Godoy, Guilherme ; Adamy, Ari ; Kaag, Matthew G. ; Bochner, Bernard H. ; Coleman, Jonathan ; Dalbagni, Guido. / The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. In: European Urology. 2010 ; Vol. 58, No. 4. pp. 574-580.
@article{ebf01a2b2371416ea457e0583f86ef90,
title = "The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center",
abstract = "Background: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. Objective: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. Design, setting, and participants: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. Intervention: All patients were treated with RNU. Measurements: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32{\%} and 78{\%}, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p = 0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p = 0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p = 0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p = 0.2). On multivariate analysis, pathologic stage (p < 0.0001) and nodal status (p = 0.01) were associated with worse CSS. This study is limited by its retrospective nature. Conclusions: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.",
author = "Favaretto, {Ricardo L.} and Shariat, {Shahrokh F.} and Chade, {Daher C.} and Guilherme Godoy and Ari Adamy and Kaag, {Matthew G.} and Bochner, {Bernard H.} and Jonathan Coleman and Guido Dalbagni",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.eururo.2010.07.003",
language = "English (US)",
volume = "58",
pages = "574--580",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

Favaretto, RL, Shariat, SF, Chade, DC, Godoy, G, Adamy, A, Kaag, MG, Bochner, BH, Coleman, J & Dalbagni, G 2010, 'The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center', European Urology, vol. 58, no. 4, pp. 574-580. https://doi.org/10.1016/j.eururo.2010.07.003

The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. / Favaretto, Ricardo L.; Shariat, Shahrokh F.; Chade, Daher C.; Godoy, Guilherme; Adamy, Ari; Kaag, Matthew G.; Bochner, Bernard H.; Coleman, Jonathan; Dalbagni, Guido.

In: European Urology, Vol. 58, No. 4, 01.10.2010, p. 574-580.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center

AU - Favaretto, Ricardo L.

AU - Shariat, Shahrokh F.

AU - Chade, Daher C.

AU - Godoy, Guilherme

AU - Adamy, Ari

AU - Kaag, Matthew G.

AU - Bochner, Bernard H.

AU - Coleman, Jonathan

AU - Dalbagni, Guido

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. Objective: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. Design, setting, and participants: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. Intervention: All patients were treated with RNU. Measurements: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p = 0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p = 0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p = 0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p = 0.2). On multivariate analysis, pathologic stage (p < 0.0001) and nodal status (p = 0.01) were associated with worse CSS. This study is limited by its retrospective nature. Conclusions: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.

AB - Background: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. Objective: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. Design, setting, and participants: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. Intervention: All patients were treated with RNU. Measurements: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p = 0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p = 0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p = 0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p = 0.2). On multivariate analysis, pathologic stage (p < 0.0001) and nodal status (p = 0.01) were associated with worse CSS. This study is limited by its retrospective nature. Conclusions: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.

UR - http://www.scopus.com/inward/record.url?scp=78649663573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649663573&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2010.07.003

DO - 10.1016/j.eururo.2010.07.003

M3 - Article

C2 - 20637540

AN - SCOPUS:78649663573

VL - 58

SP - 574

EP - 580

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -